| abstract |
The invention relates to the following components per unit dosage form, for example per tablet:n n n (a) a compound having the formula: or a pharmaceutically acceptable salt thereof as the active ingredient:n n n n n n n n (Wherein R is substituted adamantyl and n is an integer from 0 to 3);n n n (b) hydroxypropyl methylcellulose with an apparent viscosity of 80,000 cp to 120,000 cp (nominal value 100,000 cp) when present in a 2% solution;n n n (c) microcrystalline cellulose; Andn n n (d) magnesium stearaten n n It provides a pharmaceutical tablet formulation comprising a.n n n Sustained release formulations, modified release, dipeptidyl peptidase IV inhibitors, bilagliptin, pharmaceutical tablet formulations. |